Report produced on 10 September 2026 · data as of the dates shown per section Sources: official issuer documents (KID, factsheet, declared NAV series and holdings), ESMA register, ECB rates, Eurostat Public methodology: rebalix.com/en/methodology
Informational document generated by rebalix.com — facts side by side, no recommendations. It does not constitute investment advice or investment research under Directive 2014/65/EU (MiFID II). Past performance is not indicative of future results.
RebalixIE000G5ERG83 vs IE000I687JU4 · report of 10 September 2026
The funds at a glance
From official issuer documents and the ESMA register
IE000G5ERG83IE000G5ERG83Xtrackers Euro Stoxx UCITS ETF 1cEquity
Declared index
Euro STOXX NTR (EUR)
TER
0.09%
Transaction (KID)
0.00%
Fund size
4 mln EUR
Launch
18 Aug 2026
Currency
EUR
Replication
Physical
Hedging
No
Holdings
297
Distributions 12m
acc.
Effective 🇮🇹 rate
—
IE000I687JU4IE000I687JU4Xtrackers Euro Stoxx UCITS ETF 1dEquity
Declared index
Euro STOXX NTR (EUR)
TER
0.09%
Transaction (KID)
0.00%
Fund size
4 mln EUR
Launch
18 Aug 2026
Currency
EUR
Replication
Physical
Hedging
No
Holdings
297
Distributions 12m
n/a
Effective 🇮🇹 rate
—
Tracking difference — year by year
Fund minus index, from issuer-declared series (complete calendar years). Each measures adherence to its OWN index.
IE000G5ERG83n/d
not honestly computable
—
IE000I687JU4n/d
not honestly computable
—
Rebalix · IE000G5ERG83 vs IE000I687JU4section 1 of 3
RebalixIE000G5ERG83 vs IE000I687JU4 · report of 10 September 2026
296 common holdings · ticker match on full official portfolios
How the shared part is computed: for each security held by both funds, only the SMALLER of the two weights counts — a stock at 5% in one fund and 1% in the other overlaps by 1%, not 5%. Summed over all 296 common holdings this gives 100.0%: buying both funds, roughly this share of your money buys the same stocks twice. Matching is by company (one issuer does not publish security identifiers): identical holdings written differently may be missed, so the real overlap can be higher than shown.
Rebalix · IE000G5ERG83 vs IE000I687JU4section 2 of 3
RebalixIE000G5ERG83 vs IE000I687JU4 · report of 10 September 2026
Full comparison table
"—" = not published by the source, never estimated
Indicative cumulative cost: on 10,000 euro over 5 years (stated assumption: 5%/yr growth, cost = TER + transaction) ~57 euro IE000G5ERG83 · ~57 euro IE000I687JU4. Broker costs not included.
Disclaimer
This document is for information only and does not constitute investment advice under Directive 2014/65/EU (MiFID II), investment research, a personal recommendation, or an offer or solicitation to buy or sell financial instruments.
Past performance is not indicative of, nor a guarantee of, future results. The value of an investment can go down as well as up and investors may not get back the capital invested. Euro returns are affected by currency fluctuations.
Before any investment decision, read the KID and the Prospectus, available from the issuers. Tax treatment depends on individual circumstances and may change.
Data come from official issuer documents and public registers, following the public methodology at rebalix.com/en/methodology. "—" fields were not published by the source and have not been estimated. Rebalix receives no compensation from the issuers mentioned.
Rebalix · IE000G5ERG83 vs IE000I687JU4section 3 of 3